New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
07:47 EDTESRXExpress Scripts valuation already reflects Q1 miss, says Jefferies
Jefferies believes the valuation of Express Scripts shares "more than adequately" reflects the company's miss in Q1. The firm finds the stock attractive and maintains a Buy rating on the name with an $86 price target.
News For ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
Subscribe for More Information
10:43 EDTESRXExpress Scripts calls active on renewed takeover speculation
Subscribe for More Information
10:32 EDTESRXRumor: Express Scripts moves up on renewed takeover chatter
Subscribe for More Information
October 6, 2015
18:48 EDTESRXExpress Scripts to include Praluent and Repatha in its formulary
Subscribe for More Information
17:10 EDTESRXAmgen confirms Express Scripts to include Repatha on formulary
Subscribe for More Information
October 5, 2015
10:02 EDTESRXBofa/Merrill healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
October 1, 2015
13:58 EDTESRXExpress Scripts hints at slow start for new cholesterol drugs
An interview with Express Scripts' (ESRX) Everett Neville hinted at slow adoption rates for a pair of new cholesterol treatments known as PCSK9 inhibitors, spurring Piper Jaffray analysts to weigh in on the matter this morning. REJECTION RATES: In a Reuters interview published Wednesday, Express Scripts VP of Pharma Strategies and Chief Trade Relations Officer Everett Neville commented that two new PCSK9 drugs would not be "budget busters" because most prescriptions for the treatments are actually being denied. Praluent from Regeneron (REGN) and Sanofi (SNY) as well as Amgen's (AMGN) Repatha were approved in recent months to treat high cholesterol, but their $14,000-plus yearly costs have come under fire, including from the Institute for Clinical and Economic Review. "We're seeing a lot of patients who either don't qualify or their physicians are not providing [necessary] information," Neville explained, indicating that use of the cholesterol treatments is coming in at the low end of expectations. ANALYST BREAKDOWN: Piper Jaffray analyst Edward Tenthoff said Neville's statements "validate" his view that PCSK9 adoption rates would be vulnerable to pushback from reimbursers like Express Scripts. Tenthoff added that he continues to see a slow launch for Regeneron's Praluent in particular, especially given the lack of cardiovascular outcomes data. Fellow Piper Jaffray analyst Joshua Schimmer took a more optimistic view, acknowledging the apparently high prescription rejection rate but arguing that the patient pool for the drugs is expected to "grow substantially" once cardiovascular data is released. PRICE ACTION: Express Scripts shares have slipped roughly 0.9% amid broader market losses, while shares of Regeneron, Sanofi, and Amgen are all showing minor declines of less than 1%.
10:50 EDTESRXLeerink healthcare services analyst holds analyst/industry conference call
Analyst Larsen, along with Dan Steiber of D2 Pharma Consulting and James Kenney, Jr., of Harvard Pilgrim Health Care, discuss Hillary Care's potential impact to the Prescription Drug Supply Chain, the impact of the Medicaid rebate program and the uptake of bio-similars and generic launches in 2015 on an Analyst/Industry conference call to be held on October 2 at 12 pm.
05:54 EDTESRXExpress Scripts hinted at slow anti-PCSK9 launches, says Piper Jaffray
Subscribe for More Information
September 30, 2015
17:34 EDTESRXExpress Scripts says many PCSK9 prescriptions denied, Reuters reports
Subscribe for More Information
10:47 EDTESRXLeerink analyst/industry conference call date/time changed from October 8 10 am
Healthcare Distribution & Technology Larsen, along with Diplomat Pharmacy Chairman & CEO Hagerman and CFO & Secretary/Treasurer Whelan, provide industry insights including the potential impact of Hillary Care, the influence CMS may have on overall drug pricing and recent stock volatility on an Analyst/Industry conference call now being held at a new date and time of September 30 at 5 pm.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use